180 related articles for article (PubMed ID: 34654880)
1. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.
Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH
Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
5. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
6. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
7. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
9. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
10. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
11. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
12. Optimizing human α-galactosidase for treatment of Fabry disease.
Hallows WC; Skvorak K; Agard N; Kruse N; Zhang X; Zhu Y; Botham RC; Chng C; Shukla C; Lao J; Miller M; Sero A; Viduya J; Ismaili MHA; McCluskie K; Schiffmann R; Silverman AP; Shen JS; Huisman GW
Sci Rep; 2023 Mar; 13(1):4748. PubMed ID: 36959353
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
14. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
15. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
16. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
Ter Huurne M; Parker BL; Liu NQ; Qian EL; Vivien C; Karavendzas K; Mills RJ; Saville JT; Abu-Bonsrah D; Wise AF; Hudson JE; Talbot AS; Finn PF; Martini PGV; Fuller M; Ricardo SD; Watt KI; Nicholls KM; Porrello ER; Elliott DA
Am J Hum Genet; 2023 Sep; 110(9):1600-1605. PubMed ID: 37607539
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family.
Peng Y; Pan M; Wang Y; Shen Z; Xu J; Xiong F; Xiao H; Miao Y
Ren Fail; 2024 Dec; 46(2):2362391. PubMed ID: 38847497
[TBL] [Abstract][Full Text] [Related]
18. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
19. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
[TBL] [Abstract][Full Text] [Related]
20. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
